Low Leverage / Strong Balance Sheet RelativeLow reported leverage and a sizable equity base provide durable financial flexibility, allowing the company to fund development and withstand biotech R&D cycles without immediate refinancing. This structural cushion supports runway and partnership negotiating power over coming months.

Improving EPS TrajectoryMeasured EPS growth indicates an improving earnings trajectory even from negative levels, suggesting operational gains or cost control. A consistent trend of narrowing losses can materially reduce future funding needs and improves the realistic path to profitability over a multi-quarter horizon.

Reduced Cash Burn In 2024–2025 Vs 2023The reported decline in cash burn versus prior year signals more efficient capital use and better runway management. Sustained lower burn reduces dilution risk and extends time to achieve milestones or secure partnerships, a meaningful operational improvement for planning over the next 2–6 months.

Bears Say

Persistent Losses And Zero Recent RevenueZero reported revenue in the last two years and ongoing operating losses show lack of commercial scale and revenue-generating products. This structural revenue shortfall heightens reliance on development milestones and external funding, limiting margin sustainability and long-term self-funding prospects.

Consistently Negative Cash Flow; Capital DependencePersistent negative operating and free cash flow creates an enduring requirement for external financing. Dependency on new capital raises dilution and execution risks, and can constrain strategic choices if funding windows narrow or capital markets tighten over the coming quarters.

Eroding Equity And Assets TrendA multi-year decline in equity and total assets indicates loss-driven erosion of the balance sheet buffer. As net assets shrink, the company’s ability to absorb setbacks or finance growth internally weakens, making it more vulnerable to funding disruptions and strategic constraints.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.87 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €23.57M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is May 08, 2026 which is in 51 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Feb 11, 2026. The company reported -€0.069 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.069.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.982%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.